Logo

Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Share this
Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Teva Enters Into a Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Shots:

  • Polpharma Biologics has reported that its JV company- Bioeq collaborates with Teva to commercialize Bioeq’s FYB201 (biosimilar referencing Lucentis) in the EU- Canada- Israel & New Zealand
  • The launch of biosimilar ranibizumab may increase market competition- reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis while FYB201 was originally licensed from Formycon AG
  • The recent agreement with Teva complements a previous agreement with Coherus BioScience for commercialization in the US. Lucentis is a mAb fragment that has been approved to treat wet AMD

  Ref: Businesswire | Image: Bioeq

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions